NDATRANSDERMALGEL
Approved
Apr 2011
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Mechanism of Action
Androgen Receptor Agonists
Pharmacologic Class:
Androgen
Clinical Trials (5)
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Started Jun 2026
20 enrolled
Multiple SclerosisErectile DysfunctionTestosterone Deficiency
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Started Mar 2026
60 enrolled
Metastatic Castration-resistant Prostate Cancer
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Started Oct 2023
50 enrolled
Prostate Cancer
A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Started Dec 2022
28 enrolled
Biochemically Recurrent Prostate Cancer
Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
Started Dec 2022
Loss of Exclusivity
LOE Date
Oct 12, 2026
7 months away
Patent Expiry
Oct 12, 2026